Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Compassionate use of orphan drugs

20 Aug 2015

Abstract excerpt

BACKGROUND: EU regulation 726/2004 authorises manufacturers to provide drugs to patients on a temporary basis when marketing authorisation sought centrally for the entire EU is still pending. Individual Member States retain the right to approve and implement such 'compassionate use' programmes which companies will usually provide for free. Nevertheless some companies have opted not to partake in such programmes,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomedical Ethics and Regulation
Share to Biotechnology and Related Fields
Share to Health Systems, Economic Evaluations, Quality of Life

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26292942
DOI: 10.1186/s13023-015-0306-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Compassionate use of orphan drugsPMID 26292942Read ↗

Analysis of Patient Access to Orphan Drugs in TurkeySemantic proximity Read ↗

Initiatives to Promote Access to Medicines After the Publication of National Policy on Comprehensive Care of People With Rare Diseases in BrazilSemantic proximity Read ↗

The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal ProductsSemantic proximity Read ↗

Navigating the off-label drug use: Ethical and Legal guidance for cliniciansSemantic proximity Read ↗

Quantifying hope: An EU perspective of rare disease therapeutic space and market dynamicsSemantic proximity Read ↗

Preventable deaths involving medicines in England and Wales, 2013-22: a systematic case series of coroners’ reportsSemantic proximity Read ↗

Trends and variation in unsafe prescribing of methotrexate: a cohort study in English NHS primary careSemantic proximity Read ↗

Free of charge medicine schemes in the NHS. A local and regional Drug and Therapeutic Committees (DTC) experience.Semantic proximity Read ↗

Adverse drug reactions associated with the use of biological agentsSemantic proximity Read ↗

Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN networkSemantic proximity Read ↗

Trends in the Utilization of Medicines Sold in the Private Sector Post- Registration in South Africa and the Implications for Similar CountriesSemantic proximity Read ↗

Assessing the availability of Repurposed Orphan Drugs in IndiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.